PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VIR vs. VOO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between VIR and VOO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

VIR vs. VOO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Vanguard S&P 500 ETF (VOO). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-1.67%
7.99%
VIR
VOO

Key characteristics

Sharpe Ratio

VIR:

-0.01

VOO:

2.04

Sortino Ratio

VIR:

0.78

VOO:

2.72

Omega Ratio

VIR:

1.09

VOO:

1.38

Calmar Ratio

VIR:

-0.01

VOO:

3.09

Martin Ratio

VIR:

-0.02

VOO:

13.04

Ulcer Index

VIR:

28.37%

VOO:

2.00%

Daily Std Dev

VIR:

87.68%

VOO:

12.79%

Max Drawdown

VIR:

-91.89%

VOO:

-33.99%

Current Drawdown

VIR:

-87.90%

VOO:

-2.15%

Returns By Period

In the year-to-date period, VIR achieves a 36.92% return, which is significantly higher than VOO's 1.16% return.


VIR

YTD

36.92%

1M

36.73%

6M

-1.66%

1Y

0.20%

5Y*

-9.34%

10Y*

N/A

VOO

YTD

1.16%

1M

-1.97%

6M

7.17%

1Y

26.51%

5Y*

14.13%

10Y*

13.46%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VIR vs. VOO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VIR
The Risk-Adjusted Performance Rank of VIR is 4949
Overall Rank
The Sharpe Ratio Rank of VIR is 4646
Sharpe Ratio Rank
The Sortino Ratio Rank of VIR is 5555
Sortino Ratio Rank
The Omega Ratio Rank of VIR is 5151
Omega Ratio Rank
The Calmar Ratio Rank of VIR is 4747
Calmar Ratio Rank
The Martin Ratio Rank of VIR is 4646
Martin Ratio Rank

VOO
The Risk-Adjusted Performance Rank of VOO is 8282
Overall Rank
The Sharpe Ratio Rank of VOO is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of VOO is 8080
Sortino Ratio Rank
The Omega Ratio Rank of VOO is 8282
Omega Ratio Rank
The Calmar Ratio Rank of VOO is 8282
Calmar Ratio Rank
The Martin Ratio Rank of VOO is 8585
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VIR vs. VOO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Vanguard S&P 500 ETF (VOO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VIR, currently valued at -0.01, compared to the broader market-2.000.002.004.00-0.012.07
The chart of Sortino ratio for VIR, currently valued at 0.78, compared to the broader market-4.00-2.000.002.004.000.782.76
The chart of Omega ratio for VIR, currently valued at 1.09, compared to the broader market0.501.001.502.001.091.38
The chart of Calmar ratio for VIR, currently valued at -0.01, compared to the broader market0.002.004.006.00-0.013.14
The chart of Martin ratio for VIR, currently valued at -0.02, compared to the broader market-10.000.0010.0020.0030.00-0.0213.22
VIR
VOO

The current VIR Sharpe Ratio is -0.01, which is lower than the VOO Sharpe Ratio of 2.04. The chart below compares the historical Sharpe Ratios of VIR and VOO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
-0.01
2.07
VIR
VOO

Dividends

VIR vs. VOO - Dividend Comparison

VIR has not paid dividends to shareholders, while VOO's dividend yield for the trailing twelve months is around 1.23%.


TTM20242023202220212020201920182017201620152014
VIR
Vir Biotechnology, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
VOO
Vanguard S&P 500 ETF
1.23%1.24%1.46%1.69%1.25%1.54%1.88%2.06%1.78%2.02%2.10%1.85%

Drawdowns

VIR vs. VOO - Drawdown Comparison

The maximum VIR drawdown since its inception was -91.89%, which is greater than VOO's maximum drawdown of -33.99%. Use the drawdown chart below to compare losses from any high point for VIR and VOO. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-87.90%
-2.15%
VIR
VOO

Volatility

VIR vs. VOO - Volatility Comparison

Vir Biotechnology, Inc. (VIR) has a higher volatility of 49.94% compared to Vanguard S&P 500 ETF (VOO) at 4.96%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than VOO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
49.94%
4.96%
VIR
VOO
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab